OncoMatch/Clinical Trials/NCT06614686
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Is NCT06614686 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies U87 autologous CAR T-cell for nasopharynx cancer.
Treatment: U87 autologous CAR T-cell — This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U87 injection solution in patients with advanced malignant head and neck tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: TACSTD2 overexpression (intensity ≥2+, expression rate ≥40%)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: Trop2-targeted CAR-T/TCR-T cell therapy or other cellular treatments, or therapeutic cancer vaccines
Previous Trop2-targeted CAR-T/TCR-T cell therapy or other cellular treatments, or therapeutic cancer vaccines
Lab requirements
Blood counts
Adequate major organ function
Kidney function
Adequate major organ function
Liver function
Adequate major organ function
Adequate major organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06614686 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Trop2-targeted CAR-T/TCR-T cell therapy or other cellular treatments, or therapeutic cancer vaccines disqualifies patients from enrollment.
Does this trial require TACSTD2?
Yes, TACSTD2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages